Skip to main content

Advertisement

SpringerLink
Log in

Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control

  • Original Article
  • Published:
World Journal of Urology Aims and scope Submit manuscript

Abstract

Purpose

Androgen deprivation therapy (ADT) for prostate cancer (PCa) may increase peripheral insulin resistance, induce type 2 diabetes, change body composition, and alter lipoprotein profile. Some studies have reported an association between ADT and increased risk of cardiovascular events. It is known that serum level of fibrinogen (SF) is associated with coronary artery disease and increased cardiovascular risk (CVR). The aim of this study is to determine the increase in SF and C-reactive protein (CRP) of PCa patients on ADT.

Methods

Ninety-seven patients with locally advanced PCa (study group) were analyzed [mean age 73.4 years ± 6.3 SD, mean prostate specific antigen (PSA) 15.4 ng/ml ± 7.5 SD]. They were examined with blood chemistry including serum cholesterol (CHL), high density lipoproteins (HDL), low density lipoproteins (LDL), very low density lipoproteins, triacylglycerol (TAG), serum fibrinogen (FB), CRP and serum fasting glucose (SFG), serum testosterone, free testosterone at baseline, and after 12 months of ADT.

Results

Patients after 12 months of ADT (study group) had significantly higher overall serum CHL (p < 0.001), higher LDL (p = 0.01), higher FB (p < 0.001), higher serum SFG (p = 0.03) in comparison with the control group. Increase in HDL (p = 0.245) and CRP (p = 0.1) was not significant. Two patients from the study group were diagnosed with new-onset diabetes.

Conclusions

This is the first study that demonstrates the significant increase in FB in PCa patients on ADT, while CRP as inflammatory marker did not increase. Elevation of SF may contribute to increased CVR in PCa patients. Further prospective studies are warranted to confirm this association.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics 2010. CA Cancer J Clin 60:277–300

    Article  PubMed  Google Scholar 

  2. Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Prostate Cancer. 2008 Available at: http://seer.cancer.gov/statfacts/html/prost.html Accessed 25 July 2011

  3. Tangen CM, Faulkner JR, Crawford ED et al (2003) Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2:41–45

    Article  PubMed  Google Scholar 

  4. Huggins C, Stevens RE Jr, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209–223

    Article  CAS  Google Scholar 

  5. Chodak GW, Keane T, Klotz L (2002) Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology 60:201–208

    Article  PubMed  Google Scholar 

  6. Bolla M, Collette L, Blank L et al (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360:103–106

    Article  PubMed  CAS  Google Scholar 

  7. Chodak GW (1998) Comparing treatments for localized prostate cancer: persisting uncertainty. JAMA 280:1008–1010

    Article  PubMed  CAS  Google Scholar 

  8. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS (2005) Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer 103:1615–1624

    Article  PubMed  CAS  Google Scholar 

  9. Green HJ, Pakenham KI, Headley BC et al (2004) Quality of life compared during pharmacological treatments and clinical monitoring for non-localized prostate cancer: a randomized controlled trial. BJU Int 93:975–979

    Article  PubMed  CAS  Google Scholar 

  10. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS (2006) Risk of the ‘‘androgen deprivation syndrome’’ in men receiving androgen deprivation for prostate cancer. Arch Intern Med 166:465–471

    PubMed  Google Scholar 

  11. Alibhai SM, Gogov S, Allibhai Z (2006) Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: a systematic literature review. Crit Rev Oncol Hematol 60:201–215

    Article  PubMed  Google Scholar 

  12. Ziaran S, Goncalves FM, Breza J (2011) Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy. Endocr Regul 45:199–204

    Article  PubMed  CAS  Google Scholar 

  13. Daniell HW, Dunn SR, Fergusson DW, Lomas G, Niazi Z, Srtatte PT (2000) Progressive osteoporosis during andorgen deprivation therapy for prostate cancer. J Urol 163:181–186

    Article  PubMed  CAS  Google Scholar 

  14. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI (2002) Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 168(3):1005–1007

    Article  PubMed  Google Scholar 

  15. Smith MR, Lee H, Nathan DM (2006) Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 91:1305–1308

    Article  PubMed  CAS  Google Scholar 

  16. Basaria S, Muller DC, Carducci MA, Egan J, Dobs AS (2006) Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer 106(3):581–588

    Article  PubMed  CAS  Google Scholar 

  17. Smith JC, Bennett S, Evans LM, Kynaston HG, Parmar M, Mason MD, Cockcroft JR, Scanlon MF, Davies JS (2001) The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261–4267

    Article  PubMed  CAS  Google Scholar 

  18. Haseen F, Murray LJ, Cardwell CR, O’Sullivan JM, Cantwell MM (2010) The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv 4(2):128–139

    Article  PubMed  Google Scholar 

  19. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, Wilson AC, Folsom AR, Wu K, Benderly M et al (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294(14):1799–1809

    Article  PubMed  CAS  Google Scholar 

  20. Kaptoge S, White IR, Thompson SG, Wood AM, Lewington S, Lowe GD, Danesh J (2007) Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies: the fibrinogen studies collaboration. Am J Epidemiol 166(8):867–879

    Article  PubMed  CAS  Google Scholar 

  21. Palmieri V, Celentano A, Roman MJ, de Simone G, Best L, Lewis MR, Robbins DC, Fabsitz RR, Howard BV, Devereux RB (2003) Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the strong heart study. Am Heart J 145(3):467–474

    Article  PubMed  CAS  Google Scholar 

  22. Yan RT, Fernandes V, Yan AT, Cushman M, Redheuil A, Tracy R, Vogel-Claussen J, Bahrami H, Nasir K, Bluemke DA et al (2010) Fibrinogen and left ventricular myocardial systolic function: the multi-ethnic study of atherosclerosis (MESA). Am Heart J 160(3):479–486

    Article  PubMed  CAS  Google Scholar 

  23. Fibrinogen Studies Collaboration (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294:1799–1809

    Article  Google Scholar 

  24. The Emerging Risk Factors Collaboration (2010) C-reactive protein concentration and the risk of coronary heart disease, stroke, and mortality. Lancet 375:132–140

    Article  Google Scholar 

  25. Lowe GDO (1995) Fibrinogen and cardiovascular disease: historical introduction. Eur Heart J 16(Suppl A):2–5

    Article  PubMed  Google Scholar 

  26. Khosla S, Atkinson EJ, Dunstan CR, O’Fallon WM (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550–1554

    Article  PubMed  CAS  Google Scholar 

  27. Maggio M, Blackford A, Taub D, Carducci M, Ble A, Metter EJ, Braga-Basaria M, Dobs A, Basaria S (2006) Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy. J Androl 27:725–728

    Article  PubMed  CAS  Google Scholar 

  28. Elsberger B, Lankston L, McMillan DC, Underwood MA, Edwards J (2011) Presence of tumoural C-reactive protein correlates with progressive prostate cancer. Prostate Cancer Prostatic Dis 14(2):122–128

    Article  PubMed  CAS  Google Scholar 

  29. Danesh J, Collins R, Peto R, Lowe GDO (2000) Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 21:515–520

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

I certify that there is no actual or potential conflict of interest in relation to this article.

Author information

Authors and Affiliations

  1. Department of Urology, Faculty of Medicine and University Hospital, Comenius University in Bratislava, Limbova Str. 5, 831 01, Bratislava, Slovakia

    Stanislav Ziaran, Frederico Manuel Goncalves & Jan Breza Sr

Authors
  1. Stanislav Ziaran
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frederico Manuel Goncalves
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Breza Sr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stanislav Ziaran.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ziaran, S., Goncalves, F.M. & Breza, J. Patients with prostate cancer treated by ADT have significantly higher fibrinogenemia than healthy control. World J Urol 31, 289–292 (2013). https://doi.org/10.1007/s00345-012-0926-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00345-012-0926-x

Keywords

Search

Navigation